Trial Profile
An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Eyebrow Loss Due to Alopecia Areata, Alopecia Universalis or Alopecia Totalis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2019
Price :
$35
*
At a glance
- Drugs Ifidancitinib (Primary)
- Indications Alopecia; Alopecia areata
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 07 Jan 2019 Status changed from recruiting to completed.
- 14 Jun 2018 New trial record